Cyclobenzaprine is a centrally acting skeletal muscle relaxant used primarily for the short term treatment of painful muscle spasms associated with acute musculoskeletal conditions. It is generally used alongside measures such as rest and physical therapy when muscle spasm contributes to pain, stiffness, and restricted movement.
Cyclobenzaprine acts mainly within the central nervous system, particularly at the brainstem level, rather than acting directly on skeletal muscle fibers. Its pharmacological activity reduces tonic somatic motor activity and influences both gamma and alpha motor systems, helping decrease excessive muscle activity and involuntary muscle spasm.
Structurally, cyclobenzaprine is closely related to tricyclic antidepressants, although it is used primarily as a muscle relaxant rather than as an antidepressant. It also has anticholinergic and sedating properties that contribute to several of its common adverse effects.
Cyclobenzaprine is most commonly used for acute muscle spasm associated with strains, sprains, back injuries, neck injuries, and other painful musculoskeletal conditions. It can help reduce muscle tightness and improve mobility while the underlying injury heals. It is generally intended for short term treatment rather than continuous long term use.
This product provides:
- Active Ingredient: Cyclobenzaprine Hydrochloride
- Strength: 10mg per tablet
- Quantity: 100 Tablets
- Drug Class: Centrally Acting Skeletal Muscle Relaxant
- Dosage Form: Oral Tablet
- Primary Use: Acute Muscle Spasm and Musculoskeletal Pain
Cyclobenzaprine is a prescription medication in Canada and should be used under the direction of a qualified healthcare professional.
Common adverse effects include drowsiness, dizziness, dry mouth, fatigue, and reduced alertness. Because of its sedating properties, alcohol and other central nervous system depressants can increase impairment. Patients should understand how the medication affects them before driving or performing activities requiring concentration.
Cyclobenzaprine also has anticholinergic effects and should be used cautiously in individuals with conditions such as glaucoma, urinary retention, or certain cardiovascular disorders. Its structural similarity to tricyclic antidepressants is also relevant when considering potential cardiac effects and medication interactions.
Cyclobenzaprine should not be combined with monoamine oxidase inhibitors (MAOIs) or used shortly after MAOI therapy because potentially serious reactions can occur. Combining cyclobenzaprine with other serotonergic medications can also increase the risk of serotonin syndrome.
Treatment is generally intended for a limited period because muscle spasms associated with acute musculoskeletal injuries typically improve over time. The appropriate duration and treatment plan should be determined by a qualified healthcare professional.
